We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo Files for Label Expansion of Influenza Vaccine in US
Read MoreHide Full Article
GlaxoSmithKline plc (GSK - Free Report) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent – an influenza vaccine - for infants six months or older.
At present, this vaccine is approved for active immunization against influenza A subtype viruses and type B viruses, in persons three years of age and older.
Glaxo’s shares are up 9% so far this year, comparing favorably with an increase of 6.5% witnessed by the Zacks classified Large-Cap Pharma industry.
If approved, the same dose of the influenza vaccine will be eligible for all, from the age of six months and up. The sBLA was based on positive data from a phase III pivotal study evaluating the efficacy of Fluarix Quadrivalent in children six months through 35 months of age and on two supportive studies.
At the last earnings conference call, the company mentioned Glaxo saw increased demand for Fluarix/Flulaval in the U.S. in 2016. Sales of the vaccine rose 38% at constant exchange rates in the year. If approved for the label expansion, its sales could grow further.
Vaccines is one of the leading therapeutic areas for Glaxo. Overall, vaccines sales rose 14% in 2016, contributing about 16% of Glaxo’s total sales in the year. Glaxo’s vaccine business was strengthened by the acquisition of Novartis AG’s (NVS - Free Report) non-influenza Vaccines business in 2015 for $7.1 billion. The meningitis vaccines, Menveo and Bexsero, have been performing well and are a key contributor to sales growth. Glaxo’s most important vaccine product in the pipeline is its shingles vaccine, Shingrix. Glaxo has filed a regulatory application for the vaccine in both the U.S. and EU and expects approval both in the U.S. and Europe this year.
In Oct 2015, Glaxo divested two quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, to Pfizer, Inc. (PFE - Free Report) .
Shares of Summit Therapeutics rose 61.2% in the past one year while loss estimates for the current year ending Jan 2018 have narrowed around 2% in the past 60 days.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Glaxo Files for Label Expansion of Influenza Vaccine in US
GlaxoSmithKline plc (GSK - Free Report) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent – an influenza vaccine - for infants six months or older.
At present, this vaccine is approved for active immunization against influenza A subtype viruses and type B viruses, in persons three years of age and older.
Glaxo’s shares are up 9% so far this year, comparing favorably with an increase of 6.5% witnessed by the Zacks classified Large-Cap Pharma industry.
If approved, the same dose of the influenza vaccine will be eligible for all, from the age of six months and up. The sBLA was based on positive data from a phase III pivotal study evaluating the efficacy of Fluarix Quadrivalent in children six months through 35 months of age and on two supportive studies.
At the last earnings conference call, the company mentioned Glaxo saw increased demand for Fluarix/Flulaval in the U.S. in 2016. Sales of the vaccine rose 38% at constant exchange rates in the year. If approved for the label expansion, its sales could grow further.
Vaccines is one of the leading therapeutic areas for Glaxo. Overall, vaccines sales rose 14% in 2016, contributing about 16% of Glaxo’s total sales in the year. Glaxo’s vaccine business was strengthened by the acquisition of Novartis AG’s (NVS - Free Report) non-influenza Vaccines business in 2015 for $7.1 billion. The meningitis vaccines, Menveo and Bexsero, have been performing well and are a key contributor to sales growth. Glaxo’s most important vaccine product in the pipeline is its shingles vaccine, Shingrix. Glaxo has filed a regulatory application for the vaccine in both the U.S. and EU and expects approval both in the U.S. and Europe this year.
In Oct 2015, Glaxo divested two quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, to Pfizer, Inc. (PFE - Free Report) .
Glaxo has a Zacks Rank #2 (Buy).
Another Stock to Consider
A pharma stock worth considering is Summit Therapeutics plc (SMMT - Free Report) , carrying a Zacks Rank #2. You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Summit Therapeutics rose 61.2% in the past one year while loss estimates for the current year ending Jan 2018 have narrowed around 2% in the past 60 days.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>